ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis
- 31 May 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (11) , 3941-3951
Abstract
The ErbB receptor family member ErbB3 has been implicated in breast cancer growth, but it has yet to be determined whether its disruption is therapeutically valuable. In a mouse model of mammary carcinoma driven by the polyomavirus middle T (PyVmT) oncogene, the ErbB2 tyrosine kinase inhibitor lapatinib reduced the activation of ErbB3 and Akt as well as tumor cell growth. In this phosphatidylinositol-3 kinase (PI3K)-dependent tumor model, ErbB2 is part of a complex containing PyVmT, p85 (PI3K), and ErbB3, that is disrupted by treatment with lapatinib. Thus, full engagement of PI3K/Akt by ErbB2 in this oncogene-induced mouse tumor model may involve its ability to dimerize with and phosphorylate ErbB3, which itself directly binds PI3K. In this article, we report that ErbB3 is critical for PI3K/Akt-driven tumor formation triggered by the PyVmT oncogene. Tissue-specific, Cre-mediated deletion of ErbB3 reduced Akt phosphorylation, primary tumor growth, and pulmonary metastasis. Furthermore, EZN-3920, a chemically stabilized antisense oligonucleotide that targets the ErbB3 mRNA in vivo, produced similar effects while causing no toxicity in the mouse model. Our findings offer further preclinical evidence that ErbB3 ablation may be therapeutically effective in tumors where ErbB3 engages PI3K/Akt signaling. Cancer Res; 71(11); 3941–51. ©2011 AACR.Keywords
All Related Versions
This publication has 51 references indexed in Scilit:
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent ActivationCancer Research, 2010
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab TherapyJournal of Clinical Oncology, 2010
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer CellsCancer Cell, 2010
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancerVirology, 2009
- The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signalingJournal of Clinical Investigation, 2008
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997